Abstract:ABSTRACT The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccines have been widely used in the real world and shown good protective effects. A vaccine prepared from the ancestral SARS-CoV-2 receptor-binding domain (RBD) homodimer was previously made a candidate in view of its effectiveness in rodents and nonhuman primates. Here, we report that the RBD homodimers of ancestral SARS-CoV-2 as well as the variant RBD dimers from the Beta, Delta, Lambda, Omicron, and Omicron sublineages, which were rapidly prepared using our universal dimeric protein platform, elicit both strong immunogenicity and good protection in vivo . The ancestral RBD vaccine was verified to provide cross-protection against the SARS-CoV-2 Delta variant from lethal challenge. A heterogeneous booster with Omicron BA.1 dimeric RBD vaccine based on a two-dose ancestral vaccine prime reduced the viral loads in Omicron BA.1 virus-challenged animals. In addition, vaccines prepared from dimeric Omicron XBB.1.5 RBD completely protected the mice from lethal challenge by Omicron XBB.1.16 and reduced the viral infection in the respiratory tract of Syrian hamsters. Thus, RBD homodimer vaccines can confer good protection against SARS-CoV-2 and its variants when used in homogeneous or heterogeneous boosting schemes. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants achieved immune escape and became less virulent and easily transmissible through rapid mutation in the spike protein, thus the efficacy of vaccines on the market or in development continues to be challenged. Updating the vaccine, exploring compromise vaccination strategies, and evaluating the efficacy of candidate vaccines for the emerging variants in a timely manner are important to combat complex and volatile SARS-CoV-2. This study reports that vaccines prepared from the dimeric receptor-binding domain (RBD) recombinant protein, which can be quickly produced using a mature and stable process platform, had both good immunogenicity and protection in vivo and could completely protect rodents from lethal challenge by SARS-CoV-2 and its variants, including the emerging Omicron XBB.1.16, highlighting the value of dimeric recombinant vaccines in the post-COVID-19 era.

A Recombinant Receptor-Binding Domain in Trimeric Form Generates Protective Immunity Against SARS-CoV-2 Infection in Nonhuman Primates

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice

A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity

The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection

Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates

Immunization with the Receptor-Binding Domain of SARS-CoV-2 Elicits Antibodies Cross-Neutralizing SARS-CoV-2 and SARS-CoV Without Antibody-Dependent Enhancement

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

A trimeric RBD protein as a booster vaccine enhanced the humoral response and broad neutralization against SARS-CoV-2 in mice

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response

A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques

S-Trimer, a COVID-19 Subunit Vaccine Candidate, Induces Protective Immunity in Nonhuman Primates

SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung

Recombinant Receptor-Binding Domain of SARS-CoV Spike Protein Expressed in Mammalian, Insect and E. Coli Cells Elicits Potent Neutralizing Antibody and Protective Immunity

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2

A Human Antibody of Potent Efficacy Against SARS-CoV-2 in Rhesus Macaques Showed Strong Blocking Activity to B.1.351

Novel Virus-Like Nanoparticle Vaccine Effectively Protects Animal Model from SARS-CoV-2 Infection.